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ABSTRACT
Introduction: Current recommendations for
the management of rheumatoid arthritis (RA)
focus on a treat-to-target approach with the
objective of maximizing long-term health-re-
lated quality-of-life in patients with RA. Pub-
lished studies from randomized clinical trials
have reported limited data regarding the long-
term efficacy and safety of adalimumab in
patients with RA. This study aims to evaluate
the long-term (10? years) persistency and
effectiveness of adalimumab in patients with RA
in a real-world setting.
Methods: Included in this study were bio-
logic-naı¨ve adults with RA initiating adali-
mumab during follow-up enrolled in the
Corrona RA registry. More than 10 years of data
on persistency of adalimumab and rheumatol-
ogist-supplied reasons for discontinuation were
examined. Among patients who persisted on
adalimumab over the years, clinical [e.g., clini-
cal disease activity index scores (CDAI), physi-
cian global assessment, tender joint count, and
swollen joint count] and patient-reported out-
comes (PRO), such as physical function, pain,
fatigue, and morning stiffness, were examined.
Results: Of 1791 biologic-naive patients treated
with adalimumab who had C1 follow-up reg-
istry visit, 64.1% were still on therapy at 1 year
and 10.2% were still on therapy by the end of
year 12. Among patients who persisted on
adalimumab for at least 1 year (77.1% female,
mean age 53.9 years), 67.0% were in low disease
activity (LDA)/remission (CDAI B10) and had
clinically meaningful improvements from
baseline in all clinical assessments and PROs.
Initial improvements in LDA/remission and in
clinical and PRO assessments observed at year 1
were sustained in those patients who remained
on adalimumab over 10 years of follow-up.
Among patients who discontinued adali-
mumab, 61.6% were not in LDA/remission and
41.9% switched to another biologic within
12 months after discontinuing adalimumab.
Conclusions: Real-world data demonstrate a
sustained effectiveness of adalimumab in the
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INTRODUCTION
Rheumatoid arthritis (RA) is a chronic, progres-
sive inflammatory disease that can lead to irre-
versible joint damage [1], diminished function,
and disability [2]. The introduction of biologic
agents, such as tumor necrosis factor (TNF)
inhibitors, in the treatment of RA has signifi-
cantly reduceddisability amongpatientswithRA
[3] by improving clinical disease activity, physi-
cal function, radiographic outcomes, and rates of
joint surgery [4–9]. A primary goal for RA treat-
ment is to maximize the long-term health-re-
lated quality of life in patients [10]. Because RA is
a chronic and progressive disease, most patients
require long-term therapy to slow or prevent
joint damage. The average patient with RA fre-
quently needs multiple changes in therapy regi-
mens over time to achieve and maintain control
of the disease [10, 11]. Reasons to discontinue
TNF inhibitors often include intolerance, adverse
safety events, and primary or secondary loss of
efficacy [12–14]. A number of clinical trials have
provided data on the effectiveness of TNF, but for
only short periods of time [15–20]. Long-term
assessments are needed to provide a complete
understanding of the real-world benefit-risk
profile of TNF-inhibitor therapy.
Adalimumab is a TNF inhibitor that has been
proven to be efficacious in patients with RA in a
number of clinical trials [17, 20–24]. Recently,
data from long-term, open-label clinical studies
have shown that the benefits of adalimumab
therapy persist for up to 10 years [25, 26];
however, there is little information on the effect
of adalimumab therapy on long-term outcomes
in real-world settings. This study examined the
long-term (i.e., more than 10 years), real-world
persistency and effectiveness of adalimumab
using data from a large, observational RA reg-
istry (Corrona) that was prospectively and
regularly collected in the clinic from both
rheumatologists and patients.
METHODS
Study Setting
Corrona (NCT01402661) is an ongoing,
prospective, observational disease-based (all
treatmentmodalities included) registry designed
to collect information on utilization patterns,
effectiveness, and safety of therapeutic agents
used in themanagement of RA [27]. The Corrona
registry was founded by academic rheumatolo-
gists to collect data at the time of routine clinic
visits. As of January 2017, theCorronaRA registry
has recruited patients with RA from approxi-
mately 170 private and academic practice sites
across 40 states in the USA, with approximately
670 participating rheumatologists. The registry
has data on approximately 44,500 patients with
RA, 337,500 patient visits, and approximately
152,200 patient-years (PY) of follow-up observa-
tion time,withmean timeof patient follow-upof
4.2 years (median 3.5 years). Data collection,
which began in 2001, is performed at clinical
visits with follow-ups as frequent as every 3–-
6 months [28, 29]. The current analysis is a
descriptive study of long-term adalimumab
effectiveness.
All procedures followed are in accordance
with the ethical standards of the responsible
committee on human experimentation (institu-
tional and national) and with the Helsinki Dec-
laration of 1964, as revised in 2013. Approvals for
practice-level data collection and analyses are
obtained from local institutional review boards
of participating academic sites and central insti-
tutional review boards (Western and New Eng-
land Institutional Review Boards) for private
practice sites. All patients provide written
informed consent, and all data are de-identified
to protect patient confidentiality.
Study Population
The persistency assessment included all adults
with RA enrolled in the Corrona registry who
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were naı¨ve to targeted immunomodulators [i.e.,
biologics and targeted synthetic disease-modi-
fying anti-rheumatic drugs (DMARDs)] at the
time of initiation and had at least one follow-up
visit. Among this cohort, descriptive analyses
were performed for patients who had at least
12 months (±3 months visit window) of fol-
low-up while being treated with adalimumab. If
adalimumab was initiated in between registry
visits, then the visit immediately before the
adalimumab initiation visit was used to retrieve
baseline data (such as baseline disease activity)
as long as the immediately prior visit occurred
within 4 months of adalimumab initiation. If
neither of the above requirements was fulfilled,
the patient was excluded from the analysis.
Outcomes and Assessments
Patient demographics (age, sex, race, employ-
ment and insurance status) and clinical char-
acteristics (disease activity, history of
comorbidities, and treatment history) were
assessed at the time of initiation of
adalimumab.
Persistency was estimated for the overall
study population (including those with fol-
low-up\12 months) and was also stratified by
year of adalimumab initiation.
Reasons for discontinuing or switching from
adalimumab were reported by the physician.
Physicians could report up to three reasons
(related to efficacy, safety, and other) for dis-
continuing the drug. Reasons for discontinuing
because of efficacy included inadequate initial
response, failure to maintain response, and lack
of efficacy—the latter was used for cases where
not even a partial response was noted. Safety
reasons for discontinuing therapy included
serious and minor side effects. Other reasons for
discontinuing therapy included fear of future
side effects, patient preference, cost/insurance,
patient doing well, frequency of administration,
to improve tolerability, route of administration,
need for alternative mechanism of action, and
temporary interruption.
Disease activity was assessed using the Clin-
ical Disease Activity Index (CDAI) [30]. Per-
centage of time patients spent in each disease
category as defined by CDAI [remission (CDAI
B2.8), low (CDAI [2.8 to B10.0), moderate
(CDAI[10.0 to B22.0), high (CDAI[22.0)] was
estimated by linear interpolation of CDAI
between visits. An exploratory definition of flare
(defined as an increase in CDAI of 8 points; an
increase in the frequency of adalimumab use
that occurred [6 months after initiation of
adalimumab; initiation of methotrexate,
leflunomide, or sulfasalazine or increase in dose
frequency of these DMARDs that occurred
[6 months after initiation of the DMARD; an
increase in prednisone dose of C5 mg; or any
combination of these changes) was used to
determine when patients were experiencing
recurring, acute episodes of pain and inflam-
mation. Rate of flares (defined as the number of
flares/PY of follow-up) was calculated. The
components of the CDAI include swollen joint
counts (SJC 0–28 scale), tender joint counts (TJC
0–28 scale), Physician Global Assessment on a
visual analog scale (VAS 0–100 scale), and
Patient Global Assessment on a visual analog
scale (VAS 0–100).
PROs included functionality as assessed by
the modified Health Assessment Questionnaire
(mHAQ, on a scale of 0–3), Patient Global
Assessment on a VAS (0–100 scale), pain (VAS
0–100 scale), fatigue (VAS 0–100 scale), and
morning stiffness in hours categorized by
duration (0 to\1 and C1 h).
Analysis of Data
Patient characteristics, clinical outcomes, PROs,
and reasons for discontinuing therapy were
summarized using descriptive statistics and
stratified by the number of years of follow-up
during extended treatment with adalimumab.
Follow-up categories were defined as follows:
patients who had 1 year (0 to B1 year), 2 years
([1 to B2 years), 3 years ([2 to B3 years), 4 years
([3 to B4 years), 5 years ([4 to B5 years), 6 years
([5 to B6 years), 7 years ([6 to B7 years), and
8 years ([7 to B8 years) of therapy with adali-
mumab. Categories beyond 8 years were not
included because the number of patients was
too small to provide meaningful summary
statistics.
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Persistency of adalimumab therapy was esti-
mated using product limit estimator (Ka-
plan-Meier analysis), where follow-up time was
calculated as time in months from initiation of
adalimumab until discontinuation/switch of
adalimumab and last follow-up visit in Corrona;
remaining on adalimumab was considered a
censored time point. Persistency was estimated
for the overall population and also stratified by
patients who initiated adalimumab before or
during 2009 and those who initiated adali-
mumab after 2009. The year 2009 was chosen as
the cutoff point because most of the currently
approved biologics used to treat RA were on the
market. In addition, using this cutoff allowed
sufficient follow-up time to assess persistency of
adalimumab therapy in the two cohorts.
RESULTS
Study Population
As of August 2016, there were 1912 targeted
immunomodulator-naı¨ve patients who initi-
ated adalimumab in the Corrona registry. Of
these, 1791 patients had at least one follow-up
registry visit and were included in the persis-
tency analysis (Fig. 1). Among these patients,
872 had C9 months of follow-up and 746
patients had a registry visit within 4 months of
initiating adalimumab. Thus, data from
746 patients who remained on adalimumab
therapy for at least 1 year were available for
analysis of the long-term effectiveness of
adalimumab.
Baseline demographic and clinical charac-
teristics of the study population are provided in
Table 1. The average age [standard deviation
(SD)] of patients at initiation was 53.9 years
(11.8 years). Patients were predominantly
female (77.1%) and white (90.3%). The average
disease duration at the time of adalimumab
initiation was 7 years (8.4 years). The average
CDAI at initiation was 19.9 (13.6), with the
majority (73.5%) of patients in moderate
(38.1%) or severe (35.4%) disease activity. Mean
mHAQ at initiation was 0.5 (0.5) with 42.7% of
patients having an mHAQ C0.5. Most patients
(82.5%) reported experiencing morning stiff-
ness with 61.8% reporting a duration of at least
1 h.
Persistency
The persistency of adalimumab therapy is pre-
sented as a Kaplan-Meier curve (Fig. 2).
Kaplan-Meier estimates of adalimumab persis-
tency were derived using all patients who initi-
ated adalimumab therapy and had at least one
follow-up visit after initiation (N = 1791). Over
10 years of follow-up, the number of patients
still on adalimumab gradually diminished from
1791 patients at initiation to 26 patients at year
Fig. 1 Selection of study population
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10. Based on the Kaplan-Meier analysis, the
percentages of patients who remained on adal-
imumab therapy were 64.1%, 48.0%, 26.7%,
and 13.3% at 1, 2, 5, and 10 years, respectively.
The persistency of adalimumab therapy
before and after 2009 was examined in an
attempt to investigate whether the availability
of more biologics after 2009 had an impact on
persistency of adalimumab (Fig. 3). Kaplan-Me-
ier estimates of adalimumab persistency were
derived for 1075 patients who initiated adali-
mumab during or before 2009 and had at least
one registry visit after initiating adalimumab
and 837 patients who initiated adalimumab
after 2009, irrespective of whether they had a
registry visit after initiation. Overall, persistency
was significantly (p = 0.001) greater among
patients who initiated therapy before or during
2009 compared with those who initiated after
2009. For patients who initiated adalimumab
during or before 2009, 67.5%, 52.2%, and
20.7% remained on therapy at 1, 2, and 5 years,
Table 1 Baseline demographic and clinical characteristics
at adalimumab initiation
Characteristic N Adalimumab
Age (years), mean ± SD 746 53.9 ± 11.8
Female, n (%) 746 575 (77.1)
White, n (%) 740 668 (90.3)
Employed, n (%) 740 633 (85.5)
No insurance, n (%) 707 25 (3.5)
Disease duration (years),
mean ± SD
741 7.0 ± 8.4
Seropositive (RF/CCP?) 526 426 (81.0)
History of comorbidities 746
Cardiovascular diseasea, n (%) 45 (6.0)
Diabetes, n (%) 61 (8.2)
Cancerb, n (%) 35 (4.7)
SJC, mean ± SD 741 6.4 ± 6.1
TJC, mean ± SD 741 6.5 ± 6.9
Patient Global Assessment,
mean ± SD
727 38.5 ± 27.0
Physician Global Assessment,
mean ± SD
743 33.9 ± 20.9
CDAI, mean ± SD 721 19.9 ± 13.6
CDAI categories, n (%) 721
Remission (B2.8) 39 (5.4)
Low ([2.8 to B10.0) 152 (21.1)
Moderate ([10.0 to B22.0) 275 (38.1)
High ([22.0) 255 (35.4)
Pain, mean ± SD 738 41.6 ± 28.2
Fatigue, mean ± SD 281 39.6 ± 28.3
Morning stiffness, n (%) 733 605 (82.5)
Morning stiffness duration C1 h,
n (%)
595 368 (61.8)
mHAQ, mean ± SD 731 0.5 ± 0.5
DAS 28, mean ± SD 335 4.3 ± 1.6
Medication use 746
DMARD-naı¨ve, n (%) 31 (4.2)
Table 1 continued
Characteristic N Adalimumab
Monotherapy, n (%) 102 (13.7)
Combination therapy with
csDMARDsc, n (%)
644 (86.3)
Prednisone use, n (%) 246 (33.0)
CDAI clinical disease activity index, csDMARDs conven-
tional synthetic DMARDs, CV cardiovascular, DAS Dis-
ease Activity Score, DMARD disease-modifying
antirheumatic drug, mHAQ modiﬁed Health Assessment
Questionnaire, RF/CCP rheumatoid factor/cyclic citrulli-
nated peptide, SD standard deviation, SJC swollen joint
count, TJC tender joint count
a Included combined histories of myocardial infarction,
acute coronary syndrome, coronary artery disease, conges-
tive heart failure, peripheral artery disease, cardiac revas-
cularization procedure, ventricular arrhythmia, cardiac
arrest, unstable angina, stroke, transient ischemic attack,
pulmonary embolism, carotid artery disease, deep vein
thrombosis, or other cardiovascular event
b Any cancer excluding non-melanoma of the skin
c csDMARDS included hydroxychloroquine, leﬂunomide,
methotrexate, and sulfasalazine
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Fig. 2 Persistency on adalimumab. Persistency was calculated as time (months) from initiation until discontinuation of
adalimumab or last follow-up visit
Fig. 3 Persistency among patients by year of adalimumab
initiation. Persistency was calculated as time (years) from
initiation in or before 2009 until discontinuation of
adalimumab or last follow-up visit and initiation after
2009 until discontinuation of adalimumab or last fol-
low-up visit
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respectively, after initiation. For those who ini-
tiated therapy after 2009, 61.1%, 43.9%, and
22.6% remained on therapy at 1, 2, and 5 years,
respectively, after initiation.
Effectiveness of Adalimumab Over Time
Only the first 8 years of follow-up were used for
this part of the analysis to maintain statistical
power and allow meaningful conclusions (\50
patients were available for analysis afterwards).
Over 8 years of follow-up, a significant number
of patients treated with adalimumab achieved
LDA and remission. As shown in Fig. 4, LDA and
remission were noted in the majority of patients
during the first year. Specifically, 481 (67.0%),
107 (78.7%), and 52 (89.7%) patients were in
LDA/remission at years 1, 5, and 8, respectively.
Over time, the number of patients on adali-
mumab decreased and the proportion of
patients in LDA/remission increased over the
years.
Table 2 summarizes the clinical characteris-
tics and PROs of patients remaining on adali-
mumab at each year of follow-up through year
8. More patients with well-controlled disease
tended to stay on adalimumab, whereas those
without controlled disease discontinued the
medication, making the mean disease activity
lower each year. Consistent with the reduction
in disease activity seen at year 1, significant
decreases of 3.6, 4.0, and 13.5 points in mean
SJC, TJC, and pain scores, respectively, were
observed in the first year. Similar improvements
in the mean values were also seen in the Patient
and Physician Global Assessments. As shown in
Table 2, these improvements in clinical charac-
teristics and PROs remained stable over the 8--
year follow-up period for patients who
remained on adalimumab therapy. The flare
rate was 0.43 per person at year 1 and did not
increase over the follow-up period for those
patients who remained on adalimumab therapy
(Table 3). During year 1, the percentage of time
that patients spent in remission/LDA, moderate
disease activity, and high disease activity was
54.3%, 30.5%, and 15.2%, respectively. The low
levels of moderate and high disease activity
were maintained over long-term follow-up in
patients who continued adalimumab therapy.
Fig. 4 Number of patients on adalimumab, experiencing remission or LDA at baseline and at each year of follow-up. BL
baseline, HDA high disease activity, LDA low disease activity, MDA moderate disease activity
Rheumatol Ther (2017) 4:375–389 381
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Discontinuation of Therapy
Of the 105 patients who discontinued adali-
mumab therapy at year 1, only 26 (24.8%)
switched to another biologic at the registry visit
when discontinuation was reported and 44
(41.9%) had switched to another biologic by the
first year after discontinuation. A total of 33
(38.4%) patients were in LDA/remission when
they discontinued adalimumab therapy
(Table 4). Overall, 36 (34.3%) patients had a
reason reported for discontinuing therapy. Of
these, 21 discontinued because of efficacy, 6
discontinued because of side effects, and 9 dis-
continued for other reasons not related to safety
or efficacy. Available reasons for discontinua-
tion were not 100% because as opposed to how
the registry has operated in the last few years—
reporting reasons for discontinuation of bio-
logics are now mandatory—in the first years of
the registry operations the reporting of reasons
for discontinuation was not mandatory.
DISCUSSION
Long-term, real-world effectiveness data on
adalimumab in patients with RA are limited.
Observational registry data can shed light on
the long-term effectiveness of adalimumab in a
real-world setting. In this study, we followed
biologic-naı¨ve patients with RA who initiated
adalimumab and had up to 12 years of fol-
low-up. Approximately 67% of all patients who
initially started adalimumab and had
12 months of follow-up were in LDA/remission
and those who remained on adalimumab con-
tinued to do well for long periods of time. Over
5 years of follow-up, 38–53% of patients who
had a recent visit (within 4 months) before
discontinuing therapy and had a CDAI score at
that visit were in LDA/remission when they
discontinued adalimumab and only 12–25%
switched to another biologic at the time the
discontinuation was reported. Thirty-eight to
44 percent of patients started another biologic
or targeted synthetic DMARD within the 1 year
after discontinuation and 58–72% any time
after discontinuation. Approximately half
(48%) of the study population was still on
adalimumab at 2 years with satisfactory control
of their disease, and a small proportion (10%) of
patients continued to be treated for up to
12 years. Persistency was significantly greater
among patients who initiated adalimumab
therapy before or during 2009 than among
those who initiated adalimumab after 2009.
One explanation for the lower persistency after
2009 is the increased availability of other bio-
logics including agents with different mecha-
nisms of action. Another possibility is that the
follow-up period for patients initiating adali-
mumab before 2009 is longer than for those
initiating therapy after 2009.
Patient demographics in Corrona are con-
sistent with national Medicare administrative
claims data, with a higher representation of
females and older patients [31], suggesting that
the results obtained in our study are applicable
to the general population of patients with RA.
Current recommendations stress a treat-to-tar-
get approach, with achievement of remission or
LDA as a primary goal, and emphasis on
improving patient quality-of-life and function-
ality [10, 11, 32]. Our findings show that, for the
majority of patients, adalimumab offers good
disease control in a real-world setting, and for a
proportion of adalimumab-treated patients,
satisfactory disease control may persist for a
long period of time along with consistent
improvement in PROs.
Recently, two clinical trials have reported
10-year efficacy data that serve as useful com-
parisons to this real-world analysis. The PRE-
MIER [25] and DE019 [26] trials both evaluated
the efficacy and safety of adalimumab treat-
ment in combination with MTX. Both trials
involved a study population with a higher rep-
resentation of females (around 74%) and an
average age of 53 years. The PREMIER and
DE019 trials demonstrated that long-term
treatment with adalimumab and MTX offered
good disease control over 10 years of follow-up.
Comparable to the results of the Corrona anal-
ysis, the improvement of clinical characteristics
and PROs in the trials peaked within the first
year of treatment initiation, with a subsequent
plateau. Although our study did not follow
patients to determine outcomes after discon-
tinuation of adalimumab therapy, other studies
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have shown that patients who discontinue
treatment with TNF inhibitors have an increase
in the number of flares and are less likely to
maintain low disease activity [33, 34]. It should
be noted that patients enrolled in randomized
clinical trials are selected because they have
fewer significant comorbidities and fulfill very
strict inclusion criteria, which may not reflect
the real-world population. In contrast, dis-
ease-based registries, such as Corrona, include
patients with various comorbidities no matter
how severe and concomitant medications can
be more readily adjusted as needed in registry
patients. Thus, patients in Corrona are more
representative of the general population than
patients participating in randomized, con-
trolled clinical trials, making it more likely that
the persistent benefits seen with long-term
adalimumab treatment will also be observed in
the general population. Similar observational
results focusing on long-term effectiveness have
been reported in the literature reporting persis-
tence between 22% and 41% by 3 years, but
these studies did not observe patients for the
length of time ours did [35, 36]. A multitude of
other observational and registry derived data are
available which either followed patients for
fewer years [37] or had followed considerably
fewer patients [38].
A key strength of this study is the large
number of patients enrolled in Corrona and the
ability to capture medication use (including
initiation and discontinuation), clinical out-
comes, and PROs over time. Another strength of
using registry data is that all patients treated
with adalimumab were included regardless of
the presence of comorbidities or minimal dis-
ease activity measures typical of randomized
controlled trials or phase 4 follow-up of these
same patients. Limitations of the use of registry
data must be kept in mind when interpreting
the results of this study. Specifically, the registry
is limited in terms of data collection at times of
office visits and by the frequency of reporting
(3–6 months intervals between visits). There is
also an obvious channeling bias as patients who
respond well without toxicity are more likely to
remain on treatment. Thus, there may be
unidentified confounding factors associated
with this analysis. In the initial versions of the
Corrona questionnaires, reasons for discontin-
uation of therapy were not always collected.
Having all of the reasons for discontinuation
available would give a more complete picture of
why some patients discontinue adalimumab
while having relatively good control of their
disease and whether insurance concerns or
patient preference, decreased adherence, or
safety concerns played a role in the decision
process. Future studies need to focus on evalu-
ating factors associated with longer persistency
and better outcomes in a real-life population
and identifying patient and disease character-
istics that increase the persistency and effec-
tiveness of adalimumab in the long-term.
CONCLUSIONS
Results of this real-world analysis show that
adalimumab offers satisfactory disease control
in the majority of patients and that long-term
disease control is achieved for a proportion of
patients. These findings support the role of
adalimumab in achieving treat-to-target goals
and maintaining long-term disease control for
patients with RA and are consistent with
long-term results observed in clinical trials.
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